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Abstract: Low density lipoproteins (LDLs) are naturally occurring nanoparticles that are 
biocompatible, biodegradable and non-immunogenic. Moreover, the size of LDL particle is 
precisely controlled (∼22 nm) by its apoB-100 component, setting them apart from liposomes 
and lipid micelles. LDL particles have long been proposed as a nanocarrier for targeted delivery 
of diagnostics and therapeutics to LDL receptor (LDLR)-positive cancers. Here, we report the 
design and synthesis of a novel naphthalocyanine (Nc)-based photodynamic therapy (PDT) agent, 
SiNcBOA, and describe its efﬁ  cient reconstitution into LDL core (100:1 payload). Possessing a 
near-infrared (NIR) absorption wavelength (800 nm) and extremely high extinction coefﬁ  cient 
(105 M–1cm–1), SiNcBOA holds the promise of treating deeply seated tumors. Reconstituted 
LDL particles (r-Nc-LDL) maintain the size and shape of native LDL as determined by trans-
mission electron microscopy, and also retain their LDLR-mediated uptake by cancer cells as 
demonstrated by confocal microscopy. Its preferential uptake by tumor vs normal tissue was 
conﬁ  rmed in vivo by noninvasive optical imaging technique, demonstrating the feasibility of 
using this nanoparticle for NIR imaging-guided PDT of cancer.
Keywords: naphthalocyanine, lipoproteins, photodynamic therapy, near-infrared optical imag-
ing, nanoparticle, drug delivery
Introduction
Nanoscale delivery systems engineered to home to cell surface receptors overexpressed in 
speciﬁ  c malignancies hold great promise to improve our ability to treat an ever-widening 
range of cancers (Sullivan and Ferrari 2004). These carriers are often superior to drug- 
or toxin-conjugated antibodies or ligands due to their ability to deliver high payload 
drugs per receptor recognition and to integrate multiple functions (eg, image-guided 
therapy) (Ferrari 2005). However many of these nanocarriers suffer from a number 
of shortcomings, thus limiting their clinical potential. For instance, a great deal of 
efforts has been invested in addressing synthetic nanoparticles’ biocompatibility and 
toxicity issues, whereas lipid-based nanocarriers often lacks exquisite size control 
that may impact their reproducibility. Low-density lipoprotein (LDL) is the principal 
carrier of cholesterol in human plasma and delivers exogenous cholesterol to cells 
by endocytosis via the LDL receptor (LDLR) (Brown and Goldstein 1986). As an 
extraordinary high capacity (each native LDL can carry maximum 1500 cholesterol 
esters) and endogenous carrier, it is biocompatible, biodegradable and nonimmu-
nogenic (Rensen et al 2001). In addition, the size of the LDL particle is precisely 
controlled (∼22 nm) by its apoB-100 component through a network of amphipathic 
α-helix protein-lipid interactions (Lund-Katz et al 1998), setting it apart from lipo-
somes and other lipid emulsions.International Journal of Nanomedicine 2007:2(4) 768
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The potential use of LDL as nanocarriers for targeted 
delivery of diagnostic and therapeutic agents to tumor cells 
has long been recognized (Krieger et al 1979; Gal et al 1981). 
Early observations identiﬁ  ed that several hydrophobic drugs 
passively associate with plasma lipoproteins (Chassany et al 
1994). In addition, drug-lipoprotein complexes were shown 
to have favorable pharmacologic proﬁ  les for drug delivery 
(Rudling et al 1983). Thereafter several independent labo-
ratories demonstrated that various cytotoxic agents could 
be actively incorporated into lipoproteins (namely LDL) 
via intercalation or reconstitution methods (Firestone et al 
1984; Masquelier et al 1986; Lundberg 1987; Samadi-Baboli 
et al 1990). Moreover these novel LDL-drug complexes 
were shown to be more efﬁ  cacious against carcinoma cells 
than their conventional counterparts (Kader and Pater 2002). 
Experimentalists in the ﬁ  eld of nuclear medicine were the 
ﬁ  rst to demonstrate the utility of contrast agent conjugated 
LDL for imaging (Vallabhajosula et al 1988; Hay et al 1991). 
Radionuclides attached to apoB-100 or intercalated via 
amphiphilic chelates into LDL phospholipid monolayer were 
shown to be viable tracers for LDLR activity (Lees and Lees 
1991; Jasanada et al 1996). Later the incorporation of near-
infrared (NIR) ﬂ  uorescent probes into LDL showed promise 
for optical imaging (Zheng et al 2002; Li et al 2004) and 
more recently gadolinium based agents have been attached 
to LDL for improved detection of tumors using magnetic 
resonance imaging (MRI) (Corbin et al 2006). The rational 
for using LDL is based on the observation that many tumors 
actively take up LDL through the LDLR pathway (Hynds 
et al 1984; Vitols et al 1992; Caruso et al 2001). Up-regulated 
expression of LDLR in these cancer cells is thought to 
provide the substrates (cholesterol and fatty acids) needed 
for active membrane synthesis (Favre 1992). Recently, we 
developed a novel LDL rerouting technique to allow LDL 
to target any receptor of choice, thus expanding the utility 
of LDL nanocarriers far beyond the LDLR-positive tumors 
(Zheng et al 2005).
In this report, we describe the design and synthesis of 
a novel naphthalocyanine (Nc)-based photosensitizer (PS) 
as a suitable functional payload to be delivered by LDL 
nanoparticles for photodynamic therapy (PDT) (Dougherty 
et al 1998). The reason to select Nc-based PS as PDT agent 
is described as follows: (1) Nc is a neutral, porphyrin-like 
compound, that is much more stable photochemically and 
photophysically than corresponding porphyrin analogs (Ali 
and van Lier 1999). (2) Nc has photophysical properties 
consistent with its being an effective photosensitizer for PDT 
(Ali and van Lier 1999). Its 800 nm wavelength absorption 
makes Nc ideal for applications where deep tissue penetration 
is important (Weissleder and Ntziachristos 2003) and its opti-
cal absorbance is extremely high (ε  105 M-1cm-1) at this 
light wavelength. In addition, Nc is more intense and more 
red-shifted than Photofrin® at it’s optimal therapeutic wave-
length (630 nm). Nc also exceeds most second generation 
PDT agents at it’s λmax values (eg, Verteporﬁ  n® at 689 nm) 
(Dougherty et al 1998). Therefore, if the Nc-based PS can 
be reconstituted in LDL particles and be selectively deliv-
ered into tumor cells by LDLR, a tumor-targeted and NIR 
imaging-guided PDT treatment of deeply seated tumors can 
be achieved.
Here, we report the design and synthesis of tetra-t-butyl 
silicon naphthalocyanine bisoleate (SiNcBOA) suitable for 
LDL reconstitution. This report also describes the preparation 
and characterization of the Nc reconstituted LDL nanopar-
ticles (r-Nc-LDL) (see Figure 1) as well as the in vitro and 
in vivo validation of the LDLR-targeting of this r-Nc-LDL 
to cancer cells and in mice bearing human hepatoblastoma 
G2 (HepG2) tumors.
Methods and materials
Materials
UV-vis spectra were recorded on a Perkin Lambda spectro-
photometer (Boston, MA, USA). 1H NMR and 13C NMR 
spectra were recorded on Bruker ASPECT 360 MHz instru-
ment (Bruker, Billerica, MA, USA). Mass spectrometry 
analysis and elemental analysis were performed at the Mass 
Spectrometry Facility of the Department of Chemistry, 
University of Pennsylvania. All chemicals were purchased 
from Sigma-Aldrich (St. Louis, MO, USA) and all solvents 
were dried and redistilled before use. For TLC (Thin Layer 
Chromatography), EM Science TLC plates (silica gel 60 F254) 
were used.
6-tert-butyl-2,3-dihydro-1,3diimino-1H-
benz[f ]isoindole
Anhydrous NH3 was slowly bubbled through a stirred mix-
ture of 6-tert-butyl-2,3-naphthalenedicarbonitrile (4.0 g, 
17.1 mmol) in NaOMe-MeOH solution (200 ml, 0.7 g Na 
in 200 ml MeOH) for 2 h. As NH3 was introduced, the reac-
tion mixture was reﬂ  uxed for 3 h. After cooling, a portion 
of solvent was removed under reduced pressure. The result-
ing mixture stood for a while to form a yellow solid. The 
product was collected by ﬁ  ltration. The ﬁ  ltrate was poured 
into 200 mL of water with vigorous stirring. Thereafter, 
re-precipitation was performed to obtain more of the desired 
product, a yellow sticky solid. The total product obtained International Journal of Nanomedicine 2007:2(4) 769
Naphthalocyanine-reconstituted LDL nanoparticles
after washing and drying was 3.8 g (yield: 89%). This 
compound was used directly without further puriﬁ  cation.
SiNcCl2
A mixture of 6-tert-butyl-2,3-dihydro-1,3diimino-1H-
benz[f  ]isoindole (3.2 g, 12.8 mmol), SiCl4 (2 mL, 17.5 
mmol), dry tetrahydronaphthalene (20 mL), and dry tri-n-
butylamine (15 mL) was reﬂ  uxed for 2.5 h. The mixture 
was allowed to cool and diluted with methanol (25 mL). 
The product was ﬁ  ltered, washed with MeOH, and dried by 
air to acquire 1.675g green solid SiNcCl2 (yield: 51%). 1H 
NMR; δH (500 MHz; CDCl3) 1.46 (36 H, s) and 7.66–8.58 
(20 H, m); ESI-MS. Calcd. for C64H56Cl2N8Si 1034.4 found 
by ESI-MS; 1035.1 (M+H)+.
SiNc(OH)2
A mixture of crude SiNcCl2 (700 mg, 0.68 mmol) and con-
centrated H2SO4 (22 mL) was stirred for 2 h and then poured 
over ice (40 g). The solid was ﬁ  ltered, washed with water, and 
resuspended in acetone and concentrated in NH4OH (18 mL) 
to reﬂ  ux for 2 h. After cooling, the resulting solid was ﬁ  ltered 
off and dried in high vacuum to acquire 610 mg of SiNc(OH)2 
(yield: 90 %). The product was dark-green.
Oleoyl chloride
The mixture of 1 g oleic acid (3.5 mmol), 5 mL CH2Cl2, 1 mL 
SOCl2 and one drop of DMF were stirred at 40 °C for 12 h 
under argon. The CH2Cl2 and excess SOCl2 were removed 
afterwards under reduced pressure to acquire yellow sticky 
oil (oleoyl chloride) which was directly used for next step 
reaction without further puriﬁ  cation.
SiNcBOA
To the ﬂ  ask of freshly prepared oleoyl chloride, 150 mg 
(0.15 mmol) of SiNc(OH)2 and 20 mL 2-picoline were added. 
The suspension was stirred under nitrogen for 2 h. A portion 
of 4-dimethylaminopyridine (DMAP, 250 mg) was added 
to the mixture, which was then stirred under nitrogen for an 
additional 48 h at 60 °C. The solvent was removed under 
reduced pressure, and the product was puriﬁ  ed by column 
chromatography (silica gel, CH2Cl2/hexane = 4/6 (V/V)) to 
yield dark green solid, 190 mg (83%) of SiNcBOA. 1H NMR 
(300 MHz; CDCl3): δ 9.97–9.81(m, 8H), 8.85–8.44 (m 8 H), 
8.05–8.03 (m, 4H), 5.25–5.09 (m, 4H), 1.92–1.85 (m, 4H), 
1.74–1.69 (m, 36H, t-Bu), 1.65–1.60 (m, 4H), 1.27–1.20 
(m, 24H), 0.90–0.80 (m, 8H), 0.78–0.74 (m, 4H), 0.57–0.48 
(m, 4H), 0.27–0.10 (m, 4H), −0.01 −0.10 (m, 4H), −0.37 
−0.51 (m, 6H). Elemental analysis calcd. for C100H122 N8O4Si: 
C: 78.60, H: 8.05, N: 7.33; found: C: 78.77, H: 8.35, N: 6.85.
Preparation and characterization
of r-Nc-LDL
LDL, purchased from Dr. Lund-Katz’ lab at the Children’s 
Hospital of Philadelphia (Philadelphia, PA), was isolated 
Figure 1 Synthesis of SiNcBOA and SiNcBOA-reconstituted LDL nanoparticles.
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from the fresh plasma of healthy donors by sequential 
ultracentrifugation as described previously (Lund-Katz et al 
1998). LDL reconstitution with SiNcBOA was performed 
following a minor modiﬁ  cation of the method of Krieger 
(Krieger 1986) Brieﬂ  y, LDL (1.9 mg) was lyophilized with 
25 mg starch, and then extracted three times with 5 mL of 
heptane at –5 °C. Following aspiration of the last heptane 
extract, 6 mg of SiNcBOA was added in 200 μL of benzene. 
After 90 min at 4 °C, benzene and any residual heptane were 
removed under a stream of N2 in an ice salt bath for about 
45 min. The r-Nc-LDL was solubilized in 10 mM Tricine, pH 
8.2, at 4 °C for 24 h. Starch was removed from the solution 
by a low-speed centrifugation (500 × g) followed by a 20 
min centrifugation (6000 × g). The reconstituted LDL was 
stored under an inert gas at 4 °C. Similarly, r-Nc-AcLDL was 
also prepared from SiNcBOA and acetylated LDL (AcLDL, 
Biomedical Technologies, Inc.) to be used as a control. The 
protein content of the specimen was determined by the Lowry 
method (Lowry et al 1951). The absorption spectrum of 
SiNcBOA was measured after extraction with a chloroform 
and methanol mixture (2:1), and probe concentration was 
calculated based on the following formula: C = ( A/ε ) × 
D, where C is the concentration of the probe, A is the O.D. 
value, ε is the extinction coefﬁ  cient, and D is the dilution fold. 
Probe/protein molar ratio was calculated using the molecular 
mass of the ApoB-100 protein (514 kDa) knowing that one 
LDL particle contains only one ApoB-100.
Electron microscopy studies
Five microliters of the reconstituted LDL suspension was 
placed on carbon-coated 200 mesh copper grids and allowed 
to stand for 5 min. Excess sample was wicked off with 
lens paper and 2% Saturated Aqueous Uranyl Acetate was 
applied to the grid in 5 consecutive drops within 20 seconds. 
The stain was then drained off with ﬁ  lter paper and the 
grid was air dried. Digital images were taken using JEOL 
JEM 1010 electron microscope at 80 kv using AMT 12-HR 
software aided by Hamamatsu CCD Camera. All related 
supplies were purchased at Electron Microscopy Sciences 
(Fort Washington, PA, USA).
Cell preparations
LDLR overexpressing HepG2 tumor cells, obtained from 
Dr. Theo van Berkel’s laboratory from the University of 
Leiden in the Netherlands, were cultured in Dulbecco’s 
modiﬁ  ed Eagle’s medium (DMEM) supplemented with 
10% fetal bovine serum (FBS), 2 mM L-glutamine, 10 mM 
HEPES, 100 U/mL penicillin G sodium and 100 μg/mL 
streptomycin sulfate. ldlA(mSR-BI) cells lacking LDLR, 
which were obtained from Dr. Monty Krieger (Massachusetts 
Institute of Technology, Cambridge, MA), were cultured 
in F-12K medium (Ham’s Nutrient Mixture) with 2 mM 
L-glutamine, 100U/mL penicillin G sodium, 100 μg/mL 
streptomycin sulfate, 300ug/mL active G418 and 5% FBS. 
All cells were grown at 37 °C in a humidiﬁ  ed atmosphere 
containing 5% CO2. HepG2 cells (10 × 106) were inoculated 
subcutaneoulsy into the right ﬂ  anks of nude mice. The proto-
col was approved by the University of Pennsylvania Animal 
Ethics Committee.
Confocal microscopy studies
For confocal microscopy studies, HepG2 and ldlA(mSR-BI) 
cells were grown in 4-well Lab-Tek chamber slides (Naper-
ville, Illinois), respectively, at a density of 40,000 cells/well. 
Experiments were started, after two quick washes with 
pre-incubation medium (medium with 0.8% (w/v) BSA 
instead of FBS), by the addition of pre-incubation medium 
containing the indicated amounts of r-Nc-LDL. After 4 h 
incubation at 37 °C, the cells were washed three times with 
ice-cold PBS and ﬁ  xed for 15 minutes with 1% formalde-
hyde in PBS at room temperature. Then the chamber slides 
were mounted and sealed for confocal microscopy analysis. 
Confocal microscopy was performed on a Leica TCS SPII 
laser scanning confocal microscope (Heidelberg, Germany). 
Filter settings were 633 nm for excitation and 650–800 nm 
for emission.
In vivo tumor uptake of r-Nc-LDL 
monitored by Two-Channel I&Q 
Spectrometer
In vivo tumor absorption of r-Nc-LDL (140 μM, 200 μL, i.v.) 
by LDLR overexpressing HepG2 tumor was measured using a 
two channel I&Q spectrometer (Sunar et al 2006). Acetylated 
LDL reconstituted with Nc (r-Nc-AcLDL) (628 μM, 50 μL, 
i.v.) was used as the negative control to further conﬁ  rm the 
selective uptake of probe by tumor tissue. A brief descrip-
tion of I&Q spectrometer is as follows: A single 70 MHz 
radiofrequency signal from a generator is split into two parts. 
One signal is directed to the laser diode driver to amplitude 
modulate the source light intensity at 785 nm, and the other 
part is used as a reference. The intensity-modulated light is 
delivered to the tissue and the diffuse light is collected by 3 
mm diameter avalanche photo-detectors. The output signals 
are ampliﬁ  ed and band-pass ﬁ  ltered. The resulting signal 
is directed to IQ demodulators to derive the amplitude and 
phase of the signal. After low pass ﬁ  ltering, and converting International Journal of Nanomedicine 2007:2(4) 771
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signal from analog to digital, the data is collected by a laptop 
for post-processing.
Results and discussion
Design and synthesis of SiNcBOA
In order to achieve a sufﬁ  cient payload of LDL-based naph-
thalocyanine for direct targeting of PS to LDLR, a neutral 
and hydrophobic SiNcBOA, tetra-t-butyl silicon naphtha-
locyanine bisoleate, was designed for LDL reconstitution. 
The Si coordination allows the binding of two axial oleate 
ligands (Li et al 2005), whereas the bulky t-butyl groups at 
the peripheral position of the Nc macrocycle increases the 
lipophilicity of this agent, allowing for better LDL reconsti-
tution efﬁ  ciency. In addition, these ligands anchor the dye 
into the LDL phospholipid monolayer, thus preventing the 
dissociation of the dye from LDL. Moreover, the steric hin-
drance created by these ligands on each side of the Nc ring 
limits the stack aggregation usually encountered in solution 
for these porphyrin-like planar molecular structures. This 
stacking phenomenon is responsible for the decreased triplet 
lifetime and cytotoxic singlet oxygen production of such PS. 
Therefore, using this novel SiNcBOA, we anticipate a high 
and efﬁ  cient loading of this PS into LDL core.
The SiNcBOA was synthesized according to the protocol 
shown in Figure 1. The structure of SiNcBOA was conﬁ  rmed 
by 1H NMR and elemental analysis and its absorption spec-
tra showed an intense absorption at 810 nm with extinction 
coefﬁ  cient ε = 3.7 × 105 (Figure 2). This extremely high 
absorption in NIR wavelength range is ideal for treating 
deeply seated tumors, since NIR excitation light has a large 
tissue penetration (Weissleder et al 2003).
LDL nanoparticle preparation
and characterization
r-Nc-LDL was prepared by reconstituting SiNcBOA into 
LDL lipid core. The success of the reconstitution was 
evaluated by measuring the protein recovery (= protein 
content of r-Nc-LDL / protein content of total LDL for 
reconstitution). Forty-ﬁ  ve to sixty percent protein recovery 
was observed for SiNcBOA reconstituted LDL particle 
(r-Nc-LDL). Given that the UV spectrum of SiNcBOA 
is the same both before and after LDL reconstitution, the 
absorbance at 810 nm was used to calculate the SiNcBOA 
concentration in the reconstituted LDL. It was found that 
approximately 100 SiNcBOA molecules were reconstituted 
into each LDL nanoparticle.
The size of r-Nc-LDL was directly measured by electron 
microscopy. As shown in Figure 3, the mean particle size of 
r-Nc-LDL was 21.1 ± 3.4 nm (n = 25), this is about the same 
size as native LDL (20 ± 2.7 nm, n = 37). These ﬁ  ndings 
Figure 2 UV-vis spectrum of SiNcBOA.
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indicate that reconstitution of SiNcBOA into LDL did not 
change the size of the LDL particle.
In vitro validation of the LDLR-speciﬁ  c 
uptake of r-Nc-LDL
To evaluate the LDLR mediated cell uptake of r-Nc-LDL, a con-
focal microscopy study was performed on LDLR over-expressing 
HepG2 cells (LDLR+) and LDLR less-expressing ldlA(mSR-BI) 
cells (LDLR-) (Figure 4). Although the confocal laser setting (Ex. 
633nm, Em: 650 nm) is not optimal for visualizing SiNcBOA 
ﬂ  uorescence, accumulation of r-Nc-LDL into HepG2 (LDLR+) 
cells was evident and this accumulation was concentration depen-
dent (Figure 4B, 4C). The LDLR speciﬁ  c uptake of r-Nc-LDL 
is supported by the following experiments: 1) 25-fold excess 
of native LDL completely blocked the uptake of r-Nc-LDL by 
HepG2 Cells (LDLR+) (Figure 4D), 2) uptake of r-Nc-LDL into 
ldlA(mSR-BI) (LDLR-) cells was not observed even at higher 
LDL nanoparticle concentration (Figure 4F). Taken together, 
these results indicate that r-Nc-LDL was internalized into HepG2 
cells speciﬁ  cally via the LDLR mediated pathway.
In vivo validation of LDLR-speciﬁ  c 
accumulation of r-Nc-LDL
In order to validate the LDLR mediated uptake of r-Nc-LDL 
in vivo, a negative control was prepared by reconstituting 
SiNcBOA into AcLDL (r-Nc-AcLDL). The acetylated Lys 
residues of AcLDL prevent it from binding to LDLR, thus 
AcLDL serves as a valid negative control.
The two-channel I&Q spectrometer was used for in vivo 
monitoring the r-Nc-LDL nanoparticle accumulation in 
HepG2 tumors. As showed in Figure 5, signiﬁ  cant absorp-
tion enhancement was observed in tumor tissue compared to 
the surrounding muscle tissue after intravenous injection of 
the nanoparticle. The tumor to normal muscle ratio reached 
a maximum of 8:1 at 2 h post-injection. Conversely, injec-
tion of r-Nc-AcLDL into tumor-bearing mice did not result 
in absorption enhancement in either tumor or host muscle 
tissues. These ﬁ  ndings independently validate the in vivo 
LDLR-mediated uptake of r-Nc-LDL into HepG2 tumors.
Conclusions
The near infrared optical imaging/PDT agent, SiNcBOA, was 
synthesized and successfully reconstituted into LDL lipid 
core at a high payload. The LDLR targeted tumor uptake of 
this dual probe was demonstrated both in vitro by confocal 
microscopy and in vivo by I&Q spectrometry. The data dem-
onstrates that r-Nc-LDL is an efﬁ  cacious NIR optical contrast 
agent with a high absorption ε = 3.7 × 105 at 810 nm. The 
PDT efﬁ  cacy of this agent is currently under the investigation. 
Potentially, this biocompatible r-Nc-LDL nanoparticle offers 
Figure 3 EM images of native LDL (left) and r-Nc-LDL (right) nanoparticles.
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Figure 4 Confocal images of: (A) HepG2 cells alone (LDLR+), (B) HepG2 + 50 μM of r-Nc-LDL, (C) HepG2 + 200 μM of r-Nc-LDL, (D) HepG2 + 50 μM of r-Nc-LDL + 25 
fold excess native LDL, (E) ldlA(mSR-BI) cells alone (LDLR-), and (F) ldlA(mSR-BI) + 200 μM of r-Nc-LDL. The letters refer to each pair of images, with the ﬂ  uorescence 
images on the left and the bright ﬁ  eld images on the right.
the opportunity to noninvasively treat deeply-seated tumors 
with NIR imaging-guided PDT. Our laboratory has recently 
reported that by conjugating homing ligands onto the surface 
of ApoB-100, LDL can be re-directed to alternate cell surface 
receptors and epitopes (Zheng et al 2005), thus expanding 
the opportunity for therapeutic applications of this r-Nc-LDL 
nanoparticle to a wider range of tumor types.
Note
Liping Song and Hui Li contributed equally to this work.
Figure 5 I & Q spectrum of HepG2 tumor and normal muscle after r-Nc-LDL (left) or r-Nc AcLDL (right) intravenous injection.
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